FY2024 EPS Forecast for TransMedics Group Reduced by Analyst

TransMedics Group, Inc. (NASDAQ:TMDX) – Research analysts at William Blair reduced their FY2024 earnings per share (EPS) estimates for TransMedics Group in a report issued on Monday, December 2nd. William Blair analyst R. Daniels now anticipates that the company will post earnings per share of $1.04 for the year, down from their previous estimate of $1.06. The consensus estimate for TransMedics Group’s current full-year earnings is $1.01 per share. William Blair also issued estimates for TransMedics Group’s Q4 2024 earnings at $0.21 EPS, Q3 2025 earnings at $0.42 EPS, Q4 2025 earnings at $0.47 EPS, FY2025 earnings at $1.66 EPS, Q1 2026 earnings at $0.56 EPS, Q2 2026 earnings at $0.69 EPS, Q3 2026 earnings at $0.55 EPS and FY2026 earnings at $2.44 EPS.

TransMedics Group (NASDAQ:TMDX) last issued its earnings results on Monday, October 28th. The company reported $0.12 earnings per share for the quarter, missing analysts’ consensus estimates of $0.29 by ($0.17). The business had revenue of $108.76 million during the quarter, compared to analysts’ expectations of $115.00 million. TransMedics Group had a return on equity of 18.74% and a net margin of 8.14%. TransMedics Group’s quarterly revenue was up 63.7% compared to the same quarter last year. During the same period last year, the firm posted ($0.12) EPS.

A number of other research analysts have also recently commented on the company. Baird R W raised TransMedics Group to a “strong-buy” rating in a report on Tuesday, September 24th. Piper Sandler cut their price objective on TransMedics Group from $180.00 to $110.00 and set an “overweight” rating on the stock in a research report on Wednesday, November 20th. JPMorgan Chase & Co. cut their price objective on TransMedics Group from $173.00 to $116.00 and set an “overweight” rating on the stock in a research report on Tuesday, October 29th. Needham & Company LLC reissued a “hold” rating on shares of TransMedics Group in a research report on Tuesday. Finally, TD Cowen dropped their price objective on TransMedics Group from $175.00 to $120.00 and set a “buy” rating on the stock in a research report on Monday, November 18th. Two analysts have rated the stock with a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $131.80.

TransMedics Group Trading Up 1.1 %

Shares of NASDAQ:TMDX opened at $72.21 on Wednesday. The stock has a 50 day moving average of $106.99 and a 200 day moving average of $134.90. The company has a market cap of $2.42 billion, a PE ratio of 76.82 and a beta of 2.06. The company has a current ratio of 8.20, a quick ratio of 7.33 and a debt-to-equity ratio of 2.42. TransMedics Group has a 12-month low of $68.84 and a 12-month high of $177.37.

Insider Buying and Selling at TransMedics Group

In other news, Director Edward M. Basile sold 6,750 shares of the firm’s stock in a transaction on Tuesday, November 5th. The stock was sold at an average price of $83.55, for a total transaction of $563,962.50. Following the sale, the director now owns 732 shares in the company, valued at $61,158.60. This trade represents a 90.22 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO Waleed H. Hassanein sold 8,625 shares of the firm’s stock in a transaction on Monday, September 16th. The stock was sold at an average price of $153.42, for a total value of $1,323,247.50. Following the sale, the chief executive officer now owns 61,643 shares in the company, valued at $9,457,269.06. This trade represents a 12.27 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 28,042 shares of company stock valued at $3,563,985 in the last ninety days. Insiders own 7.00% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the company. International Assets Investment Management LLC acquired a new position in TransMedics Group in the second quarter worth about $47,000. USA Financial Formulas acquired a new position in shares of TransMedics Group during the third quarter worth approximately $55,000. Quarry LP boosted its position in shares of TransMedics Group by 557.1% during the third quarter. Quarry LP now owns 368 shares of the company’s stock worth $58,000 after buying an additional 312 shares during the period. National Bank of Canada FI lifted its position in TransMedics Group by 174.7% in the third quarter. National Bank of Canada FI now owns 412 shares of the company’s stock worth $65,000 after purchasing an additional 262 shares during the period. Finally, J.Safra Asset Management Corp lifted its position in TransMedics Group by 649.2% in the second quarter. J.Safra Asset Management Corp now owns 442 shares of the company’s stock worth $67,000 after purchasing an additional 383 shares during the period. 99.67% of the stock is owned by hedge funds and other institutional investors.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.